Developer docs
API playgroundTry for free, no card

Search company profiles

TRX Biosciences

Full company profile

uuid002sa53

Namestring
TRX Biosciences
Legal namestring
TRx Biosciences Limited
Company typeenum
Private
Founded yearint
2021
Descriptiontext

TRx Biosciences Limited is a UK-based, privately held pharmaceutical technology company founded in 2020 and headquartered at the Babraham Research Campus in Cambridge. The company has developed LipiCore™, a proprietary lipid-based oral drug delivery platform that exploits chylomicron-mediated uptake and unutilised transport channels to deliver small molecules and peptides to specific organs, cells and tissues while avoiding first-pass metabolism. LipiCore is positioned to address bioavailability, solubility and permeability constraints simultaneously and has demonstrated CNS penetration (drug detected in cerebrospinal fluid) and tumour uptake in early human studies.

The company operates a dual-track business model: (i) co-development and licensing partnerships with pharmaceutical companies — current partners include Oxilio (oncology, OXL001), Mandarapharma (cannabinoid CNS therapies), Monument Therapeutics (neuroinflammation, MT1980) and Arecor (oral GLP-1) — under which TRx receives upfront fees, development milestones and royalties; and (ii) a wholly-owned pipeline of four preclinical assets (TRX-611 for IBD, TRX-813 for cancer, TRX-712 for COPD, TRX-914 for depression) intended for out-licensing following clinical validation. Two co-development programmes (OXL001 and MT1980) have reported positive Phase 1 data in 2023, and a March 2024 collaboration with Arecor extends the platform into the oral peptide/GLP-1 opportunity.

The company is led by repeat biotech entrepreneurs Dr Robin Bannister (CEO; prior exits include Seebri and Arakis) and John Brew (CSO; brought Flarin to market), with advisor Dr Andy Richards CBE. TRx is funded by private life sciences specialists through a seed round completed in October 2021; no subsequent financing events are disclosed. Foundation IP for the biodistribution platform was filed in March 2021, with protection extending to at least 2041.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBabraham, United Kingdom
HQ citystring
Babraham
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oral drug delivery, pharmaceutical technology licensing, lipid-based delivery platforms, targeted biodistribution, bioavailability enhancement
Industry2 codes
PRIMARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Drug Delivery Technology
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Technology Licensing & Co-development
TypeLicensing Royalties
Description

TRx licenses its oral delivery technology to pharmaceutical partners. Partners pay upfront fees, milestone payments tied to development progress, and ongoing royalties as products advance through clinical development and commercialisation.

trxbiosciences.com
2Wholly-Owned Pipeline Development
TypeLicensing Royalties
Description

TRx develops its own proprietary product pipeline (TRX-611 for IBD, TRX-813 for Cancer, TRX-712 for COPD, TRX-914 for Depression) with the intent to out-license at optimal value following clinical validation.

trxbiosciences.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1LipiCore™
Description

TRx's proprietary oral delivery technology platform for targeted drug delivery using lipid technology.

trxbiosciences.com
Core offering1 text field

TRx Biosciences licenses its LipiCore™ lipid-based oral drug delivery platform to pharmaceutical partners to enable targeted oral delivery of small molecule drugs and peptides to specific organs, cells, and tissues. The technology exploits unexploited uptake channels and chylomicron-based transport to bypass first-pass metabolism and enhance uptake in brain and tumours. Alongside partnerships, the company develops and intends to out-license a wholly-owned pipeline covering CNS, cancer, respiratory, and inflammatory indications.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

TRX Biosciences offers a proprietary oral drug delivery technology platform called LipiCore™ that enables targeted delivery of small molecule drugs to specific organs, cells, and tissues, particularly the brain, tumors, and immune system. The technology addresses bioavailability, solubility, and permeability limitations while reducing first-pass metabolism. TRX is building both a co-development pipeline with partners (including MT1980 with Monument Therapeutics for neuroinflammation and OXL001 with Oxilio for cancer) and a wholly-owned product portfolio (TRX-611 for IBD, TRX-813 for cancer, TRX-712 for COPD, and TRX-914 for depression). The company operates through strategic partnerships while developing its own pipeline following successful technology validation.

Product and service7 records
1LipiCore™ Oral Delivery Technology
CategoryCore Technology Platform
Description

Proprietary lipid-based oral drug delivery technology platform licensed to pharmaceutical and biotech partners. Enables targeted delivery of small molecule drugs and peptides to specific organs, cells, and tissues, including brain and tumours, by exploiting unexploited uptake channels and chylomicron-based transport while avoiding first-pass metabolism.

2TRX-611
CategoryWholly Owned Pipeline Product
Description

Wholly-owned pipeline product for inflammatory bowel disease (IBD) using a novel approach to modulating the anti-inflammatory response via LipiCore™.

3TRX-813
CategoryWholly Owned Pipeline Product
Description

Wholly-owned pipeline product for cancer, involving reprofiling of a poorly absorbed anthelmintic with tumour targeting capabilities enabled by LipiCore™.

4TRX-712
CategoryWholly Owned Pipeline Product
Description

Wholly-owned pipeline product for chronic obstructive pulmonary disease (COPD) using preferential lung delivery of unexploited anti-inflammatory drugs via LipiCore™.

5TRX-914
CategoryWholly Owned Pipeline Product
Description

Wholly-owned pipeline product for depression utilising targeted brain delivery with a proven mechanism of action via LipiCore™.

6MT1980 (Co-development with Monument Therapeutics)
CategoryCo-development Product
Description

Co-development anti-inflammatory compound for neuroinflammation using TRx's brain-targeting LipiCore™ delivery, targeting Alzheimer's disease, post-operative cognitive decline, and long Covid. Demonstrated presence in cerebrospinal fluid in Phase I studies.

7OXL001 (Co-development with Oxilio)
CategoryCo-development Product
Description

Co-development novel lipid-based aprepitant formulation for pan-cancer treatment leveraging TRx's oral targeted delivery technology. Achieved dose-proportional plasma exposures in Phase 1 studies.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-12
Description

Research collaboration to develop oral GLP-1 receptor agonist product combining TRx's LipiCore™ technology with Arecor's Arestat™ formulation platform. Aimed at overcoming oral peptide delivery challenges for diabetes and obesity treatment in a market predicted to reach $80-$100+ billion by 2030. Collaboration scope for expansion to additional oral peptide products.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-06-20
Description

Development partner providing Translational Pharmaceutics® platform and clinical study facilities for Oxilio's OXL001 Phase 1 study. Quotient Sciences conducted the clinical assessments enabling accelerated development timelines.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-06-19
Description

Exclusive technology licensing and development partnership for MT1980 neuroinflammation programme. TRx technology solves pharmacokinetics and blood-brain barrier penetration issues. First-in-human Phase 1 study demonstrated drug presence in cerebrospinal fluid. TRx receives upfront payments and royalties with opportunity to broaden across Monument's portfolio.

4Mandarapharma
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-27
Description

Research agreement for cannabinoid therapy development targeting anxiety, depression, PTSD, and traumatic brain injury. TRx technology addresses oral delivery challenges and first-pass metabolism while enabling brain targeting. Partnership opportunity to expand across multiple Mandara development programmes.

trxbiosciences.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-13
Description

Research agreement for OXL001, a novel pan-cancer treatment. TRx technology addresses bioavailability and pharmacokinetic challenges while enhancing tumour uptake. TRx receives upfront, milestone, and royalty payments as Oxilio progresses development. Phase 1 study completed successfully in 2023 showing safe, dose-proportional plasma exposures.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Platform drug delivery company monetising its ENHANZE technology through royalty-bearing licensing deals with multiple pharma partners. A directly analogous business model to TRx (proprietary delivery IP, partner-led development, royalty stream).

TypeDirect peer
Description

Translational Pharmaceutics platform provider offering drug formulation development and clinical testing in an integrated service. Quotient conducted the OXL001 Phase 1 study under TRx's partnership, making it a current operational collaborator and a direct peer in accelerating oral drug formulations to first-in-human and clinical proof-of-concept.

3Diabetology Limited
TypeEmerging player
Description

Clinical-stage company developing oral formulations of peptides/metformin-class drugs. Operates in overlapping oral peptide/bioavailability space that TRx is pursuing via the Arecor collaboration and other partnerships.

TypeBroad incumbent
Description

Large CDMO with broad drug delivery, oral formulation, softgel and biologic capabilities. Catalent competes for the same partners and same oral/specialised formulation deals that TRx pursues, but operates across many dosage forms and therapeutic areas rather than TRx's targeted-delivery niche.

5Enteris BioPharma
TypeEmerging player
Description

Specialised oral peptide and small molecule formulation company with proprietary delivery technologies. Targets many of the same bioavailability and permeability problems (including oral peptides) that TRx's LipiCore addresses, putting it in the same emerging oral delivery platform cohort.

TypeBroad incumbent
Description

Global CDMO with active interest in oral biologics and bioavailability enhancement collaborations. Comparable to TRx as a broad drug-delivery platform and partner of choice for pharma companies needing formulation and process IP.

TypeBroad incumbent
Description

Established inhalation and lung drug delivery platform company. Vectura's focus on preferential lung delivery and reformulation of small molecules overlaps with TRx's lung-targeted anti-inflammatory pipeline (TRX-712 COPD) and from-founder heritage (Andy Richards advised Vectura at similar stage).

TypeDirect peer
Description

Stratified neuroscience company partnered with TRx to apply LipiCore to its MT1980 neuroinflammation programme. Demonstrates TRx's customer-of-TRx archetype (a small clinical-stage CNS biotech that adopts TRx tech), making it a peer from a customer-relationship perspective.

TypeDirect peer
Description

UK-based formulation technology company developing novel therapeutic products including oral peptides. Arecor is both a direct co-development partner of TRx (oral GLP-1 collaboration, March 2024) and a direct functional peer in lipid/excipient-driven drug delivery and reformulation of biologics and peptides for enhanced bioavailability.

TypeEmerging player
Description

Clinical-stage biotech using platform chemistry to enable delivery of difficult-to-formulate therapeutics, including CNS indications. Operates in a similar niche of solving formulation/targeting bottlenecks that limit small molecule and biologic pharmacology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TRX Biosciences

Pharmaceutical Drug Delivery Technologytrxbiosciences.com

What TRX Biosciences does

TRx Biosciences Limited is a UK-based, privately held pharmaceutical technology company founded in 2020 and headquartered at the Babraham Research Campus in Cambridge. The company has developed LipiCore™, a proprietary lipid-based oral drug delivery platform that exploits chylomicron-mediated uptake and unutilised transport channels to deliver small molecules and peptides to specific organs, cells and tissues while avoiding first-pass metabolism. LipiCore is positioned to address bioavailability, solubility and permeability constraints simultaneously and has demonstrated CNS penetration (drug detected in cerebrospinal fluid) and tumour uptake in early human studies.

The company operates a dual-track business model: (i) co-development and licensing partnerships with pharmaceutical companies — current partners include Oxilio (oncology, OXL001), Mandarapharma (cannabinoid CNS therapies), Monument Therapeutics (neuroinflammation, MT1980) and Arecor (oral GLP-1) — under which TRx receives upfront fees, development milestones and royalties; and (ii) a wholly-owned pipeline of four preclinical assets (TRX-611 for IBD, TRX-813 for cancer, TRX-712 for COPD, TRX-914 for depression) intended for out-licensing following clinical validation. Two co-development programmes (OXL001 and MT1980) have reported positive Phase 1 data in 2023, and a March 2024 collaboration with Arecor extends the platform into the oral peptide/GLP-1 opportunity.

The company is led by repeat biotech entrepreneurs Dr Robin Bannister (CEO; prior exits include Seebri and Arakis) and John Brew (CSO; brought Flarin to market), with advisor Dr Andy Richards CBE. TRx is funded by private life sciences specialists through a seed round completed in October 2021; no subsequent financing events are disclosed. Foundation IP for the biodistribution platform was filed in March 2021, with protection extending to at least 2041.

TRX Biosciences firmographics

Firmographics
Name
TRX Biosciences
Legal name
TRx Biosciences Limited
Website
https://trxbiosciences.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

TRX Biosciences industry classification

Industry
Product category
Pharmaceutical Drug Delivery Technology
NAICS
Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Oral drug delivery
  • Pharmaceutical technology licensing
  • Lipid-based delivery platforms
  • Targeted biodistribution
  • Bioavailability enhancement

Where TRX Biosciences is headquartered

Location

Headquarters

HQ city
Babraham
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

TRX Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Technology Licensing & Co-development: TRx licenses its oral delivery technology to pharmaceutical partners. Partners pay upfront fees, milestone payments tied to development progress, and ongoing royalties as products advance through clinical development and commercialisation.
  2. Wholly-Owned Pipeline Development: TRx develops its own proprietary product pipeline (TRX-611 for IBD, TRX-813 for Cancer, TRX-712 for COPD, TRX-914 for Depression) with the intent to out-license at optimal value following clinical validation.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

TRX Biosciences product offering

Product offering

Core offering

TRx Biosciences licenses its LipiCore™ lipid-based oral drug delivery platform to pharmaceutical partners to enable targeted oral delivery of small molecule drugs and peptides to specific organs, cells, and tissues. The technology exploits unexploited uptake channels and chylomicron-based transport to bypass first-pass metabolism and enhance uptake in brain and tumours. Alongside partnerships, the company develops and intends to out-license a wholly-owned pipeline covering CNS, cancer, respiratory, and inflammatory indications.

Product overview

TRX Biosciences offers a proprietary oral drug delivery technology platform called LipiCore™ that enables targeted delivery of small molecule drugs to specific organs, cells, and tissues, particularly the brain, tumors, and immune system. The technology addresses bioavailability, solubility, and permeability limitations while reducing first-pass metabolism. TRX is building both a co-development pipeline with partners (including MT1980 with Monument Therapeutics for neuroinflammation and OXL001 with Oxilio for cancer) and a wholly-owned product portfolio (TRX-611 for IBD, TRX-813 for cancer, TRX-712 for COPD, and TRX-914 for depression). The company operates through strategic partnerships while developing its own pipeline following successful technology validation.

Differentiator

Problem solved

Functional benefit

Brands

  • LipiCore™: TRx's proprietary oral delivery technology platform for targeted drug delivery using lipid technology.

Products and services

  • LipiCore™ Oral Delivery Technology Proprietary lipid-based oral drug delivery technology platform licensed to pharmaceutical and biotech partners. Enables targeted delivery of small molecule drugs and peptides to specific organs, cells, and tissues, including brain and tumours, by exploiting unexploited uptake channels and chylomicron-based transport while avoiding first-pass metabolism.
  • TRX-611 Wholly-owned pipeline product for inflammatory bowel disease (IBD) using a novel approach to modulating the anti-inflammatory response via LipiCore™.
  • TRX-813 Wholly-owned pipeline product for cancer, involving reprofiling of a poorly absorbed anthelmintic with tumour targeting capabilities enabled by LipiCore™.
  • TRX-712 Wholly-owned pipeline product for chronic obstructive pulmonary disease (COPD) using preferential lung delivery of unexploited anti-inflammatory drugs via LipiCore™.
  • TRX-914 Wholly-owned pipeline product for depression utilising targeted brain delivery with a proven mechanism of action via LipiCore™.
  • MT1980 (Co-development with Monument Therapeutics) Co-development anti-inflammatory compound for neuroinflammation using TRx's brain-targeting LipiCore™ delivery, targeting Alzheimer's disease, post-operative cognitive decline, and long Covid. Demonstrated presence in cerebrospinal fluid in Phase I studies.
  • OXL001 (Co-development with Oxilio) Co-development novel lipid-based aprepitant formulation for pan-cancer treatment leveraging TRx's oral targeted delivery technology. Achieved dose-proportional plasma exposures in Phase 1 studies.

Companies that use TRX Biosciences

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles1 record

TRX Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

TRX Biosciences partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Arecor TherapeuticscoreStrategic or Co-development Partner · 12 March 2024Research collaboration to develop oral GLP-1 receptor agonist product combining TRx's LipiCore™ technology with Arecor's Arestat™ formulation platform. Aimed at overcoming oral peptide delivery challenges for diabetes and obesity treatment in a market predicted to reach $80-$100+ billion by 2030. Collaboration scope for expansion to additional oral peptide products.
  • Quotient SciencesminorImplementation/ SI/ Consulting Partner · 20 June 2023Development partner providing Translational Pharmaceutics® platform and clinical study facilities for Oxilio's OXL001 Phase 1 study. Quotient Sciences conducted the clinical assessments enabling accelerated development timelines.
  • Monument TherapeuticscoreTechnology or Integration · 19 June 2021Exclusive technology licensing and development partnership for MT1980 neuroinflammation programme. TRx technology solves pharmacokinetics and blood-brain barrier penetration issues. First-in-human Phase 1 study demonstrated drug presence in cerebrospinal fluid. TRx receives upfront payments and royalties with opportunity to broaden across Monument's portfolio.
  • MandarapharmacoreStrategic or Co-development Partner · 27 April 2021Research agreement for cannabinoid therapy development targeting anxiety, depression, PTSD, and traumatic brain injury. TRx technology addresses oral delivery challenges and first-pass metabolism while enabling brain targeting. Partnership opportunity to expand across multiple Mandara development programmes.
  • Oxilio LimitedcoreStrategic or Co-development Partner · 13 January 2021Research agreement for OXL001, a novel pan-cancer treatment. TRx technology addresses bioavailability and pharmacokinetic challenges while enhancing tumour uptake. TRx receives upfront, milestone, and royalty payments as Oxilio progresses development. Phase 1 study completed successfully in 2023 showing safe, dose-proportional plasma exposures.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

TRX Biosciences competitors and assessment

Company assessment

Broad incumbents

  • Halozyme Therapeutics: Platform drug delivery company monetising its ENHANZE technology through royalty-bearing licensing deals with multiple pharma partners. A directly analogous business model to TRx (proprietary delivery IP, partner-led development, royalty stream).
  • Catalent: Large CDMO with broad drug delivery, oral formulation, softgel and biologic capabilities. Catalent competes for the same partners and same oral/specialised formulation deals that TRx pursues, but operates across many dosage forms and therapeutic areas rather than TRx's targeted-delivery niche.
  • Lonza Group: Global CDMO with active interest in oral biologics and bioavailability enhancement collaborations. Comparable to TRx as a broad drug-delivery platform and partner of choice for pharma companies needing formulation and process IP.
  • Vectura Group: Established inhalation and lung drug delivery platform company. Vectura's focus on preferential lung delivery and reformulation of small molecules overlaps with TRx's lung-targeted anti-inflammatory pipeline (TRX-712 COPD) and from-founder heritage (Andy Richards advised Vectura at similar stage).

Direct peers

  • Quotient Sciences: Translational Pharmaceutics platform provider offering drug formulation development and clinical testing in an integrated service. Quotient conducted the OXL001 Phase 1 study under TRx's partnership, making it a current operational collaborator and a direct peer in accelerating oral drug formulations to first-in-human and clinical proof-of-concept.
  • Monument Therapeutics: Stratified neuroscience company partnered with TRx to apply LipiCore to its MT1980 neuroinflammation programme. Demonstrates TRx's customer-of-TRx archetype (a small clinical-stage CNS biotech that adopts TRx tech), making it a peer from a customer-relationship perspective.
  • Arecor Therapeutics: UK-based formulation technology company developing novel therapeutic products including oral peptides. Arecor is both a direct co-development partner of TRx (oral GLP-1 collaboration, March 2024) and a direct functional peer in lipid/excipient-driven drug delivery and reformulation of biologics and peptides for enhanced bioavailability.

Emerging players

  • Diabetology Limited: Clinical-stage company developing oral formulations of peptides/metformin-class drugs. Operates in overlapping oral peptide/bioavailability space that TRx is pursuing via the Arecor collaboration and other partnerships.
  • Enteris BioPharma: Specialised oral peptide and small molecule formulation company with proprietary delivery technologies. Targets many of the same bioavailability and permeability problems (including oral peptides) that TRx's LipiCore addresses, putting it in the same emerging oral delivery platform cohort.
  • Noxxon Pharma: Clinical-stage biotech using platform chemistry to enable delivery of difficult-to-formulate therapeutics, including CNS indications. Operates in a similar niche of solving formulation/targeting bottlenecks that limit small molecule and biologic pharmacology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

TRX Biosciences social profiles

Digital presence

TRX Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TRX Biosciences leadership team

Management profile

Number of profiles

TRX Biosciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TRX Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TRX Biosciences

What does TRX Biosciences do?

TRx Biosciences licenses its LipiCore™ lipid-based oral drug delivery platform to pharmaceutical partners to enable targeted oral delivery of small molecule drugs and peptides to specific organs, cells, and tissues. The technology exploits unexploited uptake channels and chylomicron-based transport to bypass first-pass metabolism and enhance uptake in brain and tumours. Alongside partnerships, the company develops and intends to out-license a wholly-owned pipeline covering CNS, cancer, respiratory, and inflammatory indications.

Is TRX Biosciences a public or private company?

TRX Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was TRX Biosciences founded?

TRX Biosciences was founded in 2021. It employs 1 to 10 people.

Where is TRX Biosciences based?

TRX Biosciences is headquartered in Babraham, United Kingdom, in the Europe region.

How does TRX Biosciences make money?

Two revenue lines are on record. Technology Licensing & Co-development is the primary driver. The others are wholly-Owned Pipeline Development.

Who are TRX Biosciences's main competitors?

Broad incumbents on record are Halozyme Therapeutics, Catalent, Lonza Group and Vectura Group. Direct peers are Quotient Sciences, Monument Therapeutics and Arecor Therapeutics. Emerging players are Diabetology Limited, Enteris BioPharma and Noxxon Pharma.

Does TRX Biosciences have an API?

No public API is recorded for TRX Biosciences.

What industry is TRX Biosciences in?

TRX Biosciences's product category is Pharmaceutical Drug Delivery Technology. Its primary akta.pro industry code is HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream), with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 5417 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales